Actavis promises to invest in OTC business

19 February 2015 - Deborah Wilkes

Archived

Actavis said it would continue to invest in its OTC business, as the company announced plans to change its corporate name to Allergan after it completes the US$66 billion acquisition of the Botox maker.

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: